Vigil Neuro
Nancy Mitchell-Sweeney is a seasoned professional in clinical operations with extensive experience in the biopharmaceutical industry. Currently serving as VP and Head of Clinical Operations at Vigil Neuroscience since September 2022, Nancy has previously held significant roles at Praxis Precision Medicines, Inc., Biogen, Sanofi Genzyme, PRA Health Sciences, Execupharm, and IQVIA, where various positions included Senior Director and Associate Director. Nancy's expertise encompasses management of clinical programs in psychiatry, movement disorders, and rare diseases, with a strong background in overseeing multiple projects and project leaders across various therapeutic areas. Additionally, Nancy began a career in clinical practice as a Crisis Clinician in psychiatry at New Britain General Hospital, enhancing a robust foundation in both clinical and operational domains.
Vigil Neuro
Vigil Neuroscience is the world’s first microglia-focused therapeutics company. Their purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain’s immune system. They are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.